Arcutis Biotherapeutics director Howard G. Welgus sells 4,730 common shares for $123,835.71PUBT·1 day ago, 03:58 PMARQT-4.20%
Arcutis EVP, Chief Medical Officer Patrick Burnett disposes of USD 392,075.19 in common sharesPUBT·Aug 13 at 07:07 PMARQT-4.20%
Arcutis Biotherapeutics Earnings Call Highlights Growth MomentumTip Ranks·Aug 11 at 07:28 PMARQT-4.20%
Arcutis Biotherapeutics grants 143,500 RSUs, 37,000 stock options to new hires under inducement planPUBT·Aug 7 at 03:00 PMARQT-4.20%
Did Profitability, Higher 2026 Guidance, and New Commercial Leadership Just Recast Arcutis Biotherapeutics' (ARQT) Investment Narrative?Simplywall·Aug 6 at 12:52 PMARQT-4.20%
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Patrick Burnett Sells 955 Shares of StockMarket Beat·Aug 5 at 10:07 PMARQT-4.20%
Arcutis Biotherapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.benzinga_article·Aug 5 at 03:50 PMARQT-4.20%
Arcutis Biotherapeutics | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 129.86 MEarnings Watch·Aug 5 at 03:33 PMARQT-4.20%
Arcutis Q2 net income turns to USD 15 million; revenue rises 59% year over year to USD 129.9 millionPUBT·Aug 5 at 03:00 PMARQT-4.20%
Arcutis Biotherapeutics (ARQT) Wins FDA Filing Acceptance For ZORYVE, Is The Discount Still Justified?Simplywall·Jul 18 at 12:02 AMARQT-4.20%
Arcutis Biotherapeutics director Christopher Peetz files initial beneficial ownership statementPUBT·Jul 17 at 03:05 PMARQT-4.20%
Arcutis Biotherapeutics director Howard G. Welgus disposes of 4,730 common shares worth $127,269.30PUBT·Jul 17 at 03:02 PMARQT-4.20%
